SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2018
Commission File Number 001-38177
Clementia Pharmaceuticals Inc.
(Translation of registrant’s name into English)
4150 St Catherine Street West, Suite 550
Montreal, Quebec, Canada, H3Z 2Y5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBITS INCLUDED AS PART OF THIS REPORT
| Exhibit | ||
| 99.1 | Report of Voting Results | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clementia Pharmaceuticals Inc. | ||||||
| Date: May 31, 2018 | By: | /s/ Michael Singer | ||||
| Name: | Michael Singer | |||||
| Title: | Chief Financial Officer | |||||
Exhibit 99.1
CLEMENTIA PHARMACEUTICALS INC.
ANNUAL MEETING OF SHAREHOLDERS
MONTRÉAL QUÉBEC, CANADA
TUESDAY, MAY 29, 2018
REPORT OF VOTING RESULTS
In accordance with section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, the following sets out the matters voted on at the annual meeting of shareholders (the "Meeting") of Clementia Pharmaceuticals Inc. (the "Corporation") held on Tuesday, May 29, 2018. Each of the matters set out below are described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of the Corporation dated April 17, 2018. According to the scrutineer's report, shareholders were present at the Meeting, in person or by proxy, representing 22,315,487 common shares or 70.36% of the 31,717,584 shares outstanding on the April 19, 2018 record date for the Meeting.
1. Election of Directors
At the Meeting, management of the Corporation presented to the shareholders its nominees for directors. According to the proxies received and a vote by show of hands, all of management’s nominees were elected as directors of the Corporation to hold office until the next annual meeting of shareholders of the Corporation or until their successors are elected or appointed.
The proxies submitted for the Meeting on this matter were as follows:
| Name of Nominee | Total Number of Votes For | Total Number of Votes Withheld | ||
| Dr. David Bonita | 20,023,372 | 96.72% | 678,800 | 3.28% |
| Dr. Clarissa Desjardins | 20,702,172 | 100% | - | 0% |
| Dr. Robert Heft | 20,702,172 | 100% | - | 0% |
| Dr. Francois Nader | 20,677,506 | 99.88% | 24,666 | 0.12% |
| Dr. Allan Mandelzys | 20,702,172 | 100% | - | 0% |
| Pierre Legault | 20,702,172 | 100% | - | 0% |
| Jean-François Pariseau | 20,702,172 | 100% | - | 0% |
2. Appointment of Auditors
At the Meeting, shareholders were asked to approve the appointment of KPMG LLP, as auditors of the Corporation until the close of the next annual meeting of shareholders or until a successor is appointed, at remuneration to be fixed by the board of directors. According to the proxies received and vote by show of hands, the resolution was approved.
The proxies submitted for the Meeting on this matter were as follows:
| Total Number of Votes For | Total Number of Votes Withheld |
| 21,442,469 (99.999%) | 213 (0.001%) |